Trial Profile
Phase II Study Evaluating the Combination of Temsirolimus and Sorafenib in the Treatment of Radioactive Iodine Refractory Thyroid Cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Sorafenib (Primary) ; Temsirolimus (Primary)
- Indications Thyroid cancer
- Focus Therapeutic Use
- 18 Jul 2018 Status changed from active, no longer recruiting to completed.
- 02 Jan 2018 Planned End Date changed from 1 Dec 2017 to 1 Dec 2018.
- 02 Jan 2018 Planned primary completion date changed from 1 Dec 2017 to 1 Dec 2018.